No phaseStatus unknown
Fat Incorporation through omega-3 Supplementation to determine immune cellular changes
Lipid Incorporation through poly-unsaturated fatty acid (PUFA) Supplementation: Yielding Nutrient-driven Cellular responses
- Sponsor
- Baker Heart and Diabetes Institute
- Enrolment
- 60 planned
- Conditions
- Immune cell function; Inflammatory and Immune System - Normal development and function of the immune system
- Interventions
- High-dose omega-3 fatty acid supplementation (Arm 2) Participants will receive oral omega-3 polyunsaturated fatty acid (n-3 PUFA; approximately 4800 mg/day) supplementation containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks
- Ages
- adults
- Registry
- ACTRN12626000962336
Full record on ANZCTRSource: WHO ICTRP, processed 10 August 2026
Primary outcomes
- Change in immune cell membrane omega-3 fatty acid composition[Immune cell membrane fatty acid composition will be quantified using targeted lipidomic analysis (liquid chromatography-mass spectrometry, LC-MS/MS). The primary endpoint is the change in fatty acid incorporation into immune cell membrane
History
Started
Last registry update
Registered